Immuno-positron emission tomography (immunoPET) with 89Zr-labeled antibodies has
shown great potential in cancer imaging. It can provide important information about the …

Inert and stable radiolabeling of monoclonal antibodies (mAb), antibody fragments, or
antibody mimetics with radiometals is a prerequisite for immuno-PET. While radiolabeling is …

Targeted alpha-particle therapy (TAT) aims to selectively deliver radionuclides emitting α-
particles (cytotoxic payload) to tumors by chelation to monoclonal antibodies, peptides or …

Over the past two decades, bioorthogonal chemistry has become a preferred tool to achieve
site‐selective modifications of proteins. However, there are only a handful of commonly …

Although antibodies are well developed and widely used in cancer therapy and diagnostic
fields, some defects remain, such as poor tissue penetration, long in vivo metabolic …

Antibodies and their derivatives radiolabelled with positron-and gamma-emitting
radiometals enable sensitive and quantitative molecular Positron Emission Tomography …

Radioimmunotherapy (RIT) is FDA-approved for the clinical management of liquid
malignancies, however, its use for solid malignancies remains a challenge. The putative …

The growing advancement in nuclear medicine challenges researchers from several
different fields to integrate imaging and therapeutic modalities in a theranostic …

The ability to modify biologically active molecules such as antibodies with drug molecules,
fluorophores or radionuclides is crucial in drug discovery and target identification. Classic …

Rationale: The overwhelming majority of radioimmunoconjugates are produced via random
conjugation methods predicated on attaching bifunctional chelators to the lysines of …